Refine by
Immunotherapy For The Treatment Equipment & Supplies
15 equipment items found
Manufactured by:HAL Allergy Group based inLeiden, NETHERLANDS
Our sublingual (SLIT) product is a high-dose treatment with proven long-term efficacy. With an administration of a few drops under the tongue, the patient can carry out the treatment at home and it allows for an individually tailored treatment. Sublingual immunotherapy is available for a wide range of respiratory allergens. ...
Manufactured by:BioLingus AG based inHergiswil, SWITZERLAND
Due to the fact that BioLingus drug administration is sublingual, and the use of a specific carrier molecule in the BioLingus formulation, the BioLingus technology is particularly effective for sublingual immuno ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UGN-301 is UroGen’s in-licensed anti-CTLA-4 antibody (zalifrelimab). UGN-201 is our proprietary formulation of imiquimod, a toll-like receptor 7 (TLR 7) agonist. When combined, these medicines stimulate both the innate (UGN-201) and adaptive (UGN-301) immune responses, both of which are important for fully harnessing the power of the immune system to fight ...
Manufactured by:BriaCell Therapeutics Corp. based inWest Vancouver, BRITISH COLUMBIA (CANADA)
We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type. We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, allowing for matching of over 99% of patients with advanced breast cancer. A simple saliva test is used to determine the HLA-type of each ...
Manufactured by:Inovarion based inParis, FRANCE
The latest advances in cancerology have made it possible to dissect the complexity of the signaling pathways leading to cancerous pathologies. New lines of thought have thus been drawn up in terms of therapies and tumor characterization. The mechanisms of oncogenesis, resistance to treatments and the identification of diagnostic biomarkers are major areas of research. Our teams can intervene on a ...
Manufactured by:Tactiva Therapeutics based inBuffalo, NEW YORK (USA)
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, billions of cancer fighting immune cells are manufactured in a special facility, and given back to the ...
Manufactured by:Intrommune Therapeutics based inNew York, NEW YORK (USA)
Intrommune has developed a novel drug delivery platform—oral mucosal immunotherapy (OMIT)—for the treatment of food allergies. Therapeutic agents are embedding in fully functioning toothpaste so that treatment can be conveniently administered during a patient’s daily toothbrushing ...
Manufactured by:TVAX Biomedical, Inc. based inOlathe, KANSAS (USA)
TVAX®’s second candidate (TVI-Kidney-1) is being evaluated for the treatment of kidney cancer and targets stage 4 renal cell ...
Manufactured by:TVAX Biomedical, Inc. based inOlathe, KANSAS (USA)
TVAX®’s lead candidate (TVI-Brain-1) is being evaluated for the treatment of brain cancer and targets glioblastomas. The drug candidate has received Fast Track Designation by the US Food and Drug Administration (FDA) to test TVI-Brain-1 in a Phase 2b clinical study for glioblastoma multiforme (GBM). The Fast Track Designation is supported by positive Phase 2 clinical data, as well as ...
by:Oncimmune Holdings PLC based inNottingham, UNITED KINGDOM
Oncimmune’s proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers that can help stratify patients in multiple cancer indications and with different autoimmune ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory B-cell precursor acute lymphoblastic leukemia (ALL) and relapsed / refractory diffuse large B-cell ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates created from clonal master engineered iPSC lines as off-the-shelf cancer immunotherapies for the treatment of hematologic malignancies and solid ...
Manufactured by:BlueWillow Biologics based inAnn Arbor, MICHIGAN (USA)
Food allergy has become a significant health problem with increasing incidence and severity, particularly in children but continuing throughout adulthood. There is no cure for food allergy, and allergic reactions can be life threatening. According to the Centers for Disease Control, an estimated 8% of children in the U.S. are now affected by food allergies, or roughly 2 students per ...
Manufactured by:Heska Corporation based inLoveland, COLORADO (USA)
The safest long term allergy treatment solution for canine, feline or equine ...